Eli Lilly And Co (LLY) Shares Bought by HT Partners LLC

HT Partners LLC increased its stake in shares of Eli Lilly And Co (NYSE:LLY) by 15.9% during the 4th quarter, HoldingsChannel reports. The fund owned 4,367 shares of the company’s stock after purchasing an additional 600 shares during the quarter. Eli Lilly And Co comprises about 0.2% of HT Partners LLC’s portfolio, making the stock its 15th biggest position. HT Partners LLC’s holdings in Eli Lilly And Co were worth $505,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Balasa Dinverno & Foltz LLC grew its position in Eli Lilly And Co by 15.9% during the 3rd quarter. Balasa Dinverno & Foltz LLC now owns 3,629 shares of the company’s stock worth $389,000 after purchasing an additional 499 shares during the last quarter. Arizona State Retirement System grew its position in Eli Lilly And Co by 0.8% during the 3rd quarter. Arizona State Retirement System now owns 278,567 shares of the company’s stock worth $29,893,000 after purchasing an additional 2,174 shares during the last quarter. Blair William & Co. IL grew its position in Eli Lilly And Co by 4.0% during the 3rd quarter. Blair William & Co. IL now owns 245,801 shares of the company’s stock worth $26,377,000 after purchasing an additional 9,532 shares during the last quarter. Russell Investments Group Ltd. grew its position in Eli Lilly And Co by 26.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 906,840 shares of the company’s stock worth $97,186,000 after purchasing an additional 188,150 shares during the last quarter. Finally, FMR LLC grew its position in Eli Lilly And Co by 172.9% during the 2nd quarter. FMR LLC now owns 1,188,301 shares of the company’s stock worth $101,398,000 after purchasing an additional 752,864 shares during the last quarter. Hedge funds and other institutional investors own 77.02% of the company’s stock.

Shares of NYSE:LLY traded up $0.26 during midday trading on Friday, hitting $116.20. The stock had a trading volume of 2,127,343 shares, compared to its average volume of 5,031,224. The company has a market cap of $124.16 billion, a price-to-earnings ratio of 27.15, a PEG ratio of 1.68 and a beta of 0.33. The company has a quick ratio of 1.53, a current ratio of 1.91 and a debt-to-equity ratio of 0.83. Eli Lilly And Co has a 1 year low of $73.69 and a 1 year high of $119.84.

Eli Lilly And Co (NYSE:LLY) last issued its earnings results on Tuesday, November 6th. The company reported $1.39 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.35 by $0.04. The business had revenue of $6.06 billion for the quarter, compared to the consensus estimate of $6.04 billion. Eli Lilly And Co had a net margin of 1.85% and a return on equity of 42.84%. The business’s quarterly revenue was up 7.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.05 earnings per share. On average, research analysts forecast that Eli Lilly And Co will post 5.59 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, March 8th. Stockholders of record on Friday, February 15th will be issued a $0.645 dividend. This is an increase from Eli Lilly And Co’s previous quarterly dividend of $0.56. The ex-dividend date of this dividend is Thursday, February 14th. This represents a $2.58 annualized dividend and a dividend yield of 2.22%. Eli Lilly And Co’s payout ratio is presently 52.57%.

In related news, SVP Myles O’neill sold 25,000 shares of the firm’s stock in a transaction dated Monday, December 10th. The shares were sold at an average price of $112.92, for a total value of $2,823,000.00. Following the completion of the sale, the senior vice president now owns 26,562 shares in the company, valued at $2,999,381.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 174,696 shares of the firm’s stock in a transaction dated Wednesday, October 17th. The shares were sold at an average price of $113.25, for a total transaction of $19,784,322.00. Following the completion of the sale, the insider now owns 119,005,804 shares of the company’s stock, valued at approximately $13,477,407,303. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,702,736 shares of company stock worth $124,427,811. Insiders own 0.11% of the company’s stock.

Several research analysts have issued reports on LLY shares. Zacks Investment Research raised shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $133.00 price objective on the stock in a research report on Wednesday, December 5th. Guggenheim started coverage on shares of Eli Lilly And Co in a research report on Monday, October 8th. They set a “buy” rating on the stock. Cantor Fitzgerald reissued a “buy” rating and set a $128.00 price objective on shares of Eli Lilly And Co in a research report on Wednesday, October 17th. Barclays reissued an “overweight” rating and set a $112.00 price objective (up from $107.00) on shares of Eli Lilly And Co in a research report on Tuesday, September 18th. Finally, Wolfe Research started coverage on shares of Eli Lilly And Co in a research report on Tuesday, October 23rd. They set a “market perform” rating and a $119.00 price objective on the stock. Ten equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $111.50.

WARNING: “Eli Lilly And Co (LLY) Shares Bought by HT Partners LLC” was first published by WKRB News and is the property of of WKRB News. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.wkrb13.com/2019/01/11/eli-lilly-and-co-lly-shares-bought-by-ht-partners-llc.html.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: Capital gains and your 401(k) or IRA

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply